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Abstract: The polydentate ligand 3-[(2-hydroxybenzylidene)amino]-2-thioxo-
imidazolidin-4-one was synthesized in the intermolecular cyclocondensation 
reaction of 2-hydroxybenzaldehyde thiosemicarbazone and ethyl chloroacetate. 
A novel palladium(II) complex was obtained from cis-[Pd(DMSO)2Cl2] by 
nucleophilic substitution of both DMSO ligands with the iminic nitrogen and 
the thiolactamic sulfur from the ligand. The structures of the compounds were 
characterized based on their spectral data. The cytotoxic activities of the ligand 
and the palladium(II) complex were studied on the tumor cell lines: human co-
lon carcinoma HCT-116 and SW-480 cells using the MTT viability test. The 
results showed that the investigated palladium(II) complex had a significantly 
greater cytotoxic effect compared to that of the ligand. 
Keywords: thiohydantoins; palladium(II) complexes; cytotoxic activity. 
INTRODUCTION 
Thiohydantoins are sulfur analogs of hydantoins with one or both carbonyl 
group(s) replaced by a thiocarbonyl group.1–5 Among the known thiohydantoins, 
2-thiohydantoins (2-thioxoimidazolidin-4-ones) are the most well known due to 
their wide applications as intermediates and reagents as well as therapeutics, her-
bicides and fungicides. They are traditionally considered as useful intermediates 
in peptide synthesis and structure determination.6 2-Thiohydantoins are also used 
for other purposes, including textile printing,7 as catalysts for polymerizations,8 
in the production of resins and plastics9 and as qualitative reagents for the detec-
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tion of some metal ions upon complexation.10 Thiohydantoins and their deriva-
tives exist in many natural products.11–13 In the past decades, great efforts have 
been devoted to introducing thiohydantoins and their derivatives into desirable 
substrates, such as pharmacophores and synthetic intermediates.14–17 Com-
pounds containing the thiohydantoin structural motif have been identified to dis-
play a wide range of biological activities. For example, many of them exhibit 
anticonvulsant,18 anti-epileptic,19 antimicrobial,20 antiviral,21 antineoplastic,22 
hypolipidemic,23 antithrombotic,24 and potential antitumor activities,25,26 etc. 
Several derivatives are employed either as established drugs in clinical practice2 
or as fungicides and herbicides in agriculture.27  
It is known28 that coordination of these compounds with transition metal 
ions sometimes enhances their antiviral and antitumor activities. 2-Thiohydantoin 
molecules contain a thioamide fragment and can undergo thione–thiol tautome-
rism,29 due to which they can be coordinated to metal ions through the lone elec-
tron pairs of the nitrogen or sulfur atoms, or both. Coordination with some tran-
sition metals was previously studied.30–35. The resulting complexes can contain 
2-thiohydantoins as either neutral ligands or monoanions, which are formed upon 
deprotonation of the N–H group.36–40 Most of the resulting complexes contain 
four-membered metalla-cycles. 
Thiohydantoin molecules containing substituents with an additional donor 
atom can form chelate40–43 or supramolecular44 complexes in which the metal 
atom is coordinated by one or two thiohydantoin ligands in the neutral or depro-
tonated form. 
The synthesis of coordination compounds that incorporate the thiohydantoin 
nucleus could have significant impact in the field of drug design and drug deli-
very.  
In this paper, the synthesis and spectroscopic characterization of a palla-
dium(II) complex of 3-[(2-hydroxybenzylidene)amino]-2-thioxoimidazolidin-4- 
-one is described. The cytotoxic activities of the ligand and its palladium(II) 
complex were studied on two tumor cell lines of human colon carcinoma using 
the MTT viability test. 
EXPERIMENTAL 
Starting materials 
All chemicals were purchased from commercial sources (Sigma-Aldrich, Fluka or Cen-
trohem) and were used without further purification. Solvents were purified and dried by 
standard methods. Dimethyl sulfoxide (DMSO) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide (MTT) were obtained from Serva, Germany. Dublecco’s modified 
Eagle medium (DMEM) was obtained from Gibco Invitrogen. Fetal bovine serum (FBS) and 
trypsin–EDTA were obtained from PAA-The cell culture company, Austria.  
Cis-[Pd(DMSO)2Cl2]45 and 2-hydroxybenzaldehyde thiosemicarbazone46 1 were synthe-
sized according to literature methods. 
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Instrumentations 
The elemental analyses were performed by standard micro-methods using an Elemental 
Vario ELIII CHNSO analyzer. 
The IR spectra were recorded on a Perkin-Elmer FTIR spectrometer, model Spectrum 
One. 
The 1H- and 13C-NMR spectra were recorded on a Varian Gemini 2000 spectrometer at 
200 and 50 MHz, respectively, in DMSO-d6 solution using TMS as internal standard. D2O 
exchange was applied to confirm the assignment of the nitrogen- and oxygen-bound protons. 
The UV–Vis spectra were recorded on a Perkin-Elmer Lambda 35 double beam spectro-
photometer in 1.00 cm quartz Suprasil cells. 
The X-ray powder diffraction (XRPD) patterns were obtained on a Philips PW 1710 
automated X-ray powder diffractometer using a Cu tube operated at 40 kV and 35 mA. The 
instrument was equipped with a diffracted beam curved graphite monochromator and a Xe-
filled proportional counter. The diffractometer was calibrated with a silicon standard sample. 
For the Rietveld profile fitting method, the diffraction data were collected using the step-
scanning mode in the 2θ range between 4 and 130° with 0.02° steps. The counting time was 
fixed to 5 s per step. The collected data were refined using FullProff software. 
Ligand synthesis 
The procedure for preparation of 3-[(2-hydroxybenzylidene)amino]-2-thioxoimidazo-
lidin-4-one 2 was analogous to that described previously.46 A mixture of 5.100 g 1 (26.15 
mmol) and 3.204 g ethyl chloroacetate (26.15 mmol) in absolute methanol (150 cm3) in the 
presence of 6.433 g fused sodium acetate (78.45 mmol) was heated under reflux for 6 h. The 
reaction mixture was cooled and poured into water. The precipitate was separated by filtra-
tion, washed with cold water and dried. The crude product was recrystallized from hot me-
thanol. Yield: 4.548 g.  
Complex synthesis 
The synthesis of palladium(II) complex with 3-[(2-hydroxybenzylidene)amino]-2-thio-
xoimidazolidin-4-one 3 was achieved by dissolving 0.178 g 2 (0.76 mmol) in 10 cm3 of ab-
solute methanol under reflux until dissolution and then adding 10 cm3 of a methanolic solu-
tion of Pd(DMSO)2Cl2 (0.252 g, 0.76 mmol) in three portions. Reaction mixture was heated 
under reflux for 12 h, cooled to 0 °C and the resulting orange–red precipitate was separated by 
filtration, washed with hot water, small amount of hot methanol and dried. The complex was 
recrystallized from hot methanol. Yield: 0.180 g. 
Antiproliferative assay 
Tumor cell lines were obtained from the American Type Culture Collection. The cells 
were maintained in DMEM supplemented with 10 % FBS, with 100 units mL-1 penicillin and 
100 µg mL-1 streptomycin. The cells were cultured in a humidified atmosphere with 5 % CO2 
at 37 °C. The cells were grown in 75 cm2 culture bottles supplied with 15 mL DMEM, and 
after a few passages, the cells were plated in a 96-multiwell plate (104 cells well-1). All studies 
were realized with cells at 70 to 80 % confluence. After 24 h of incubation of the cells, the 
medium was replaced with 100 μL medium containing various doses of 2 and 3 (0.1, 1, 10, 
50, 100 and 500 μM) for 24 and 72 h. Untreated cells served as the control. After 24 and 72 h 
of treatment, the cell viability was determined by the MTT assay.47 The proliferation test is 
based on the color reaction of mitochondrial dehydrogenase in living cells with MTT. At the 
end of the treatment period, MTT (final concentration 5 mg mL-1 PBS) was added to each 
well, which was then incubated at 37 °C in 5 % CO2 atmosphere for 2–4 h. The colored crys-
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tals of the produced formazan were dissolved in 150 μL DMSO. The absorbance was mea-
sured at 570 nm on Microplate Reader (Elisa 2100C). Cell proliferation was calculated as the 
ratio of the absorbance of the treated group divided by the absorbance of the control group, 
multiplied by 100 to give the percentage proliferation.  
Biological activity was the result of one individual experiment, performed in triplicate 
for each dose. The magnitude of correlation between the variables was determined using an 
SPSS (Chicago, IL) statistical software package (SPSS for Windows, ver. 17, 2008). The 
effect of each extract are expressed by IC50 (inhibitory dose which inhibits 50 % of cell 
growth) and by the magnitude of maximal effect in exposed cells. The IC50 values were 
calculated from the dose curves using the CalcuSyn computer program. 
RESULTS AND DISCUSSION 
The polydentate ligand, 3-[(2-hydroxybenzylidene)amino]-2-thioxoimidazo-
lidin-4-one 2, was obtained by intermolecular cyclocondesation reaction of 2-
hydroxybenzaldehyde thiosemicarbazone and ethyl chloroacetate (Scheme 1).46 
Yield: 74.0 %. Anal. Calcd. for C10H9N3O2S: C, 51.05; H, 3.86; N, 17.86 
%. Found: C, 51.08; H, 3.88; N, 17.89 %; IR (KBr, cm–1): 3443 (O–H), 3318 
(NH), 3173, 3031 (CH Ar), 2987, 2808 (CH2), 1721 (C=O), 1616 (C=N), 1604, 
1538, 1490 (C=C Ar), 1464, 1368, 1282, 1266 (C=S), 1202 (C–O), 1112, 1062, 
949, 830, 753 (δ CH Ar), 627; 1H-NMR (DMSO-d6, δ / ppm): 3.97 (2H, s, CH2), 
6.94 (2H, m, H1–, H2–Ar), 7.30 (1H, dt, J = 7.8 and 1.8 Hz, H3–Ar), 7.75 (1H, 
dd, J = 8.0 and 1.9 Hz, H4–Ar), 8.64 (1H, s CH=N), 10.88 (1H, s OH), 12.06 
(1H, bs NH); 13C-NMR (50 MHz, DMSO-d6, δ / ppm = 33.53 (CH2), 116.51, 
118.63, 119.69, 130.76, 132.34, 156.60 (Ar), 158.19 (C=N), 174.04 (C=O), 
177.94 (C=S); UV–Vis (DMSO, λmax / nm): 305.91, 338.97, 351.14. 
The novel palladium(II) complex 3 was obtained by nucleophilic substitution 
of both DMSO ligands from cis-[Pd(DMSO)2Cl2] with the iminic nitrogen and 
thiolactamic sulfur from ligand 2 (Scheme 2). A non-charged complex was iso-
lated as an orange–red amorphous precipitate. The metal complex was non-hyg-
roscopic, soluble in DMSO, sparingly soluble in methanol and ethanol and inso-
luble in water. The analytical data revealed 1:1 (metal:ligand) stoichiometry. The 
structures of the ligand and complex were established by its elemental compo-
sition and IR, NMR and electronic spectra. 
Yield: 57.7 %. Anal. Calcd. for C10H9Cl2N3O2PdS: C, 29.11; H, 2.22; N, 
10.18 %. Found: C, 29.08; H, 2.18; N, 10.16 %; IR (KBr, cm–1) 3436 (O–H), 
3153 (NH), 2925 (CH2), 2853, 1719 (C=O), 1602 (C=N), 1533, 1400, 1385, 1332 
(C=S), 1254, 1201 (C–O), 1154, 755 (δ CH Ar); 1H-NMR (DMSO-d6, δ / ppm): 
3.16 (2H, s CH2), 6.64 (1H, t, J = 7.0 Hz, H2–Ar), 6.93 (1H, d, J = 8.0 Hz, H1–
Ar), 7.29 (1H, dt, J = 8.6 and 1.9 Hz, H3–Ar), 7.48 (1H, dd, J = 7.6 and 1.9 Hz, 
H4–Ar), 8.10 (1H, s CH=N), 9.78 (1H, s OH), 10.89 (1H, bs NH). 13C- 
-NMR (50 MHz, DMSO-d6, δ / ppm) 48.77 (CH2), 115.32, 118.12, 119.67, 
133.47, 134.26, 148.71 (Ar), 161.31 (C=N), 169.91 (C=O), 193.26 (C=S). UV– 
–Vis (DMSO, λmax / nm): 259.25, 304.72, 340.39, 403.33. 
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Spectroscopic characterization 
In order to confirm complex formation and gain insight into the structure of 
obtained compounds, the IR spectra of the free ligand and its complex were re-
corded. The absence of the strong band at ≈2500 cm–1, assignable to the ν(S–H) 
mode, indicate that both compounds exist in the thiono (C=S) form in the solid 
state. Comparison of vibrational frequencies of the free ligand with those of the 
complex showed a shift in the C=S band to a higher frequency by 66 cm–1. This 
is evidence that the thionic sulfur atom was involved in the coordination.32,48 In 
addition, the C=N absorption band was shifted to a lower frequency by 14 cm–1. 
Consequently, the iminic nitrogen atom is also presumably involved in the co-
ordination.49 The non-coordination of O is shown by the C=O band shifting only 
very slightly upon complexation. The broad band observed in region 3153 cm–1 
due to N–H stretch was shifted in complex, probably because of an adjustment in 
the current arising due to coordination of the thionic sulfur. 
Further evidence for the coordinating mode of the thiohydantoin 2 was ob-
tained from the NMR spectra in DMSO-d6. In the 1H-NMR spectrum of the li-
gand, there is no resonance at ca. 4.0 ppm, attributed to the resonance of the –SH 
proton, while the appearance of a broad peak at 12.06 ppm due to the –NH pro-
ton indicates that even in a polar solvent such as DMSO, it remains in the thione 
form. Such a large chemical shift for an –NH proton was already reported for si-
milar systems.50 Various types of primary and secondary hydrogen bond interact-
tions are possible in the studied system. The phenolic H-atom could form an in-
tramolecular hydrogen bond with the iminic nitrogen and additionally, as donat-
ing bifurcated, with the carbonyl group (Fig. 1). This proposal was confirmed ex-
perimentally by recording the 1H-NMR spectrum of ligand 2 in the presence of 
NaOH. Upon transformation of the ligand into the phenolate form, the OH proton 
at 10.88 ppm disappeared while the other protons shift upfield (the –NH proton 
shifted from 12.06 to 10.98 ppm, Fig. 2.) This fact also could explain the upfield 
shifts of the corresponding signals in complex 3. It seems that coordination pre-
vented the formation of an intramolecular hydrogen bond because after complex-
ation, iminic nitrogen has no lone electron pair. The –NH proton signal of the 
thiohydantoin shifted upfield and appeared at 10.89 ppm in complex 3. The up-
Fig. 1. Intramolecular hydrogen bond inter-
action in ligand 2. 
__________________________________________________________________________________________________________________________
2013 Copyright (CC) SCS
Available online at shd.org.rs/JSCS/
 PALLADIUM(II) COMPLEX WITH 2-THIOHYDANTOIN 223 
field shift of the iminic proton signal by 0.54 ppm is clear evidence for coordi-
nation by the iminic nitrogen. 
 
Fig. 2. 1H-NMR spectra of ligand 2 (a) and ligand 2 after the addition of a small amount of 
solid NaOH (b). 
The 13C-NMR chemical shifts of the C=S and C=N resonances reflected the 
involvement of the sulfur from the thiohydantoin ring and the iminic nitrogen in 
an intermolecular interaction.  
Based on foregoing discussion, the ligand behaves as a neutral NS-bidentate 
coordinative agent towards the palladium(II) ion. 
In the electronic spectra, two intense absorption bands were exhibited at 305.91 
and 351.14 nm for the ligand and at 304.72 and 403.33 nm for the complex. 
Three d–d spin allowed singlet–singlet and three spin forbidden singlet–triplet 
transitions are predicted for square-planar complexes of palladium(II). However, 
strong charge-transfer transitions may interfere and prevent the observation of 
some of the expected bands, especially for complexes containing sulfur donor 
atoms.51 The prominent strong band at 403.33 nm was assigned to a combination 
of intraligand and ligand to metal charge transfer absorptions and d–d bands, 
which supports the idea of a square-planar environment for the metal ion.  
In the XRPD pattern of the ligand 2, low intensity and fairly broad peaks 
showed the poor crystallinity of the substance. The low intensities, poorly de-
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fined peaks on the XRPD pattern of complex 3 demonstrated its low degree of 
crystallinity. The broad hump around 10° 2θ indicates the existence of an amor-
phous phase and might represent extremely poor or partial crystallinity of com-
plex 3. The existence of an amorphous hump between 6 and 15° 2θ in the pattern 
of complex 3 is obvious in comparison with the ligand 2. In addition, there is no 
clear phase transition, but the metal–ligand complex disrupted the structure, 
causing the poor crystallinity demonstrated in the diffraction pattern. 
Due to the poor solubility of the isolated complex in suitable solvents, no 
single crystal of sufficient quality could be obtained. Therefore, attention was fo-
cused on spectroscopic methods for the structural characterization of complex 3, 
which suggested coordination of the ligand to palladium via the iminic nitrogen 
and the thionic sulfur (Scheme 2). 
Antiproliferative activity 
After seeding in standard DMEM medium, the cells were exposed to diffe-
rent concentrations of ligand 2 and complex 3 for 24 and 72 h at 37 °C. The re-
sults obtained with the antiproliferative assays are represented through IC50 va-
lues (Table I). 
Comparing the cytotoxic effect of the complex and ligand, a significant dif-
ference was observed. Namely, while the complex exerted extreme cytotoxicity 
with IC50 values for 72-h treatment of 6.51 and 8.89 µM for HCT-116 and SW-
480 cell lines respectively (Table I), the ligand did not show a considerable cyto-
toxic effect, even though decreased cell viability was generated with increasing 
ligand concentration. 
TABLE I. Growth inhibitory effects – IC50 values (μM) of the Pd(II) complex and its ligand 
on HCT-116 and SW-480 cell lines after 24 and 72 h of treatment 
Compound HCT-116 SW-480 
24 h 72 h 24 h 72 h 
Pd(II) complex 16.98±0.21 6.51±0.02 15.73±0.25 8.89±0.36 
Ligand 336.75±2.20 >500 >500 366.00±2.55 
Cisplatin 293.52±2.36 58.55±1.23 325.19±2.35 49.58±1.54 
Complex 3 exerted very high cytotoxic activity, i.e., with increasing com-
plex concentration, the cytotoxicity increased. A statistically significant diffe-
rence in cytotoxicity after 24 h of treatment was noticed compared to that after 72 
h of treatment. Interestingly, studying the complex activity it was shown that 
sensitivity of investigated cell lines are of similar extent.  
Considering the cytotoxicity of the ligand, it was noticed from the IC50 va-
lues (Table I) and from the measured absorbances that the cytotoxicity increased 
with increasing applied concentration of the ligand. It was shown that the SW- 
-480 cells exhibited greater sensitivity to the ligand 72 h after treatment (IC50 = 
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366 µM) compared to after 24 h (> 500 µM). Interestingly, the HCT-116 cells 
show exactly the opposite trend, i.e., a greater cytotoxic effect was observed 24 h 
(IC50 = 337 µM) after treatment compared to after 72 h (> 500 µM). This was 
probably due to the acute effect of the investigated ligand on the SW-480 cells. 
Although the cytotoxicity of the ligand was quantified and statistically processed, 
it is important to notice that this cytotoxic effect was certainly not significant, 
especially in comparison with the activity of the complex. 
The results show that the investigated complex had a significantly greater 
cytotoxicity compared to that of cisplatin and further opened up the possibility 
for the synthesis of similar complexes of palladium(II). 
CONCLUSIONS 
A novel palladium(II) complex was synthesized by substitution reaction of 
cis-[Pd(DMSO)2Cl2] with a 2-thiohydantoin type ligand. Based on spectral data, 
it is proposed that 3-[(2-hydroxybenzylidene)amino]-2-thioxoimidazolidin-4-one 
acts as a bidentate ligand, making use of the thiolactamic sulfur and iminic nitro-
gen for coordination to the central metal ion. The cytotoxicity of this complex was 
investigated on two independent colon cancer cell lines (HCT-116 and SW-480) 
using the MTT viability test. The complex exhibited very high cytotoxic activity 
and showed a cytotoxic effect that was much better than that of the ligand. The 
observed cytotoxicity could be pursued to obtain a potential chemotherapeutic 
drug. 
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И З В О Д  
СИНТЕЗА, КАРАКТЕРИЗАЦИЈА И ЦИТОТОКСИЧНОСТ ПАЛАДИЈУМ(II) КОМПЛЕКСА 
СА 3-[(2-ХИДРОКСИБЕНЗИЛИДЕН)АМИНО]-2-ТИОКСОИМИДАЗОЛИДИН-4-ОНОМ 
БИЉАНА ШМИТ1, РАДОСЛАВ З. ПАВЛОВИЋ1, АНА РАДОСАВЉЕВИЋ-МИХАИЛОВИЋ2, АЊА ДОШЕН2, 
МИЛЕНА Г. ЋУРЧИЋ1, ДРАГАНА С. ШЕКЛИЋ1 и МАРКО Н. ЖИВАНОВИЋ1 
1Природно–математички факултет, Универзитет у Крагујевцу, Радоја Домановића 12, п. пр. 60, 
34000 Крагујевац и 2Институт за нуклеарне науке Винча, п. пр. 522, 11001 Београд 
Полидентатни лиганд, 3-[(2-хидроксибензилиден)амино]-2-тиоксоимидазолидин-4-
он синтетисан је интермолекулском циклокондензацијом 2-хидроксибензалдехидтио-
семикарбазона и етил-хлороацетата. Нов паладијум(II) комплекс добијен је нуклео-
филном супституцијом оба DMSO лиганда из cis-[Pd(DMSO)2Cl2] иминским азотом и тиолактамским сумпором из лиганда. Структуре једињења су окарактерисане на основу 
њихових спектралних података. Цитотоксична активност лиганда и паладијум(II) ком-
плекса испитивана је на туморским ћелијским линијама: хуманог карцинома колона 
HCT-116 и SW-480 помоћу МТТ теста вијабилности. Испитивани паладиjум(II) ком-
плекс испољава веома висок цитотоксични ефекат, много бољи од лиганда.  
(Примљено 25. маја, ревидирано 21. децембра 2012) 
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